Hübel K, Dale D C, Engert A, Liles W C
Department of Medicine, University of Washington, Seattle, WA, USA.
J Infect Dis. 2001 Jan 15;183(2):321-328. doi: 10.1086/317943. Epub 2000 Dec 8.
The transfusion of neutrophils, or granulocyte transfusion therapy, has long been considered as a logical approach to the treatment of severe bacterial and fungal infections in patients with prolonged neutropenia or intrinsic defects in neutrophil function. However, despite numerous clinical trials, the efficacy and safety of granulocyte transfusion therapy remain controversial. Efficacy has been compromised largely by the inability to transfuse sufficient quantities of functionally active neutrophils to patients. The recent use of recombinant granulocyte colony-stimulating factor (G-CSF) to mobilize neutrophils in donors before centrifugation leukapheresis has rekindled interest in the potential clinical applications of granulocyte transfusion therapy. This review focuses on the use of G-CSF for donor stimulation and summarizes the current status of granulocyte transfusion therapy for treatment of infectious diseases.
输注中性粒细胞，即粒细胞输注疗法，长期以来一直被视为治疗长期中性粒细胞减少或中性粒细胞功能存在内在缺陷患者严重细菌和真菌感染的合理方法。然而，尽管进行了大量临床试验，粒细胞输注疗法的疗效和安全性仍存在争议。疗效在很大程度上受到无法向患者输注足够数量功能活跃的中性粒细胞的影响。最近使用重组粒细胞集落刺激因子（G-CSF）在离心白细胞单采前动员供体中的中性粒细胞，重新引发了人们对粒细胞输注疗法潜在临床应用的兴趣。本综述重点关注G-CSF用于供体刺激的情况，并总结粒细胞输注疗法治疗传染病的现状。
